This will enable detailed analysis of the expression levels of key enzymes involved in the FASN and sphingolipid metabolism pathways (e.g., CerS, SMPD, etc.), providing insights into the mechanisms of ceramide upregulation in ALL patients. This evidence concerns the gene FASN and acute lymphoblastic leukemia.